# EDGAR Filing Document

**Accession Number:** 0001843575
**File Stem:** 0001843575-23-000002
**Filing Date:** 2023-3
**Character Count:** 8432
**Document Hash:** 5f2b73c68424658f9adbc0b7d71eb575
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001843575-23-000002.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001843575-23-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230228

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bassaganya-Riera Josep
- **CENTRAL INDEX KEY:** 0001843575

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39971
- **FILM NUMBER:** 23701446

**MAIL ADDRESS:**
- **STREET 1:** 1800 KRAFT DRIVE
- **STREET 2:** SUITE 100
- **CITY:** BLACKSBURG
- **STATE:** VA
- **ZIP:** 24060

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Riera Josep Bassaganya
- **DATE OF NAME CHANGE:** 20210201
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Landos Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001785345
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 815085535
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1800 KRAFT DRIVE, SUITE 216
- **CITY:** BLACKSBURG
- **STATE:** VA
- **ZIP:** 24060
- **BUSINESS PHONE:** 540-818-2844

**MAIL ADDRESS:**
- **STREET 1:** 1800 KRAFT DRIVE, SUITE 216
- **CITY:** BLACKSBURG
- **STATE:** VA
- **ZIP:** 24060

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bassaganya-Riera Josep<br><sub>(Last) (First) (Middle)</sub><br>1800 KRAFT DRIVE<br>SUITE 100<br><sub>(Street)</sub><br>BLACKSBURG, VA 24060<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Landos Biopharma, Inc. [ LABP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| common stock | 2023-02-28 |  | S<sup>(1)</sup> |  | 3470736 | D | <sup>(1)</sup> | 0 | I | by trust<sup>(2)</sup> |
| common stock | 2023-02-28 |  | S<sup>(1)</sup> |  | 467306 | D | <sup>(1)</sup> | 0 | I | by GRAT<sup>(3)</sup> |
| common stock | 2023-02-28 |  | S<sup>(1)</sup> |  | 496527 | D | <sup>(1)</sup> | 0 | I | by GRAT<sup>(4)</sup> |
| common stock | 2023-02-28 |  | S<sup>(1)</sup> |  | 500000 | D | <sup>(1)</sup> | 0 | I | by GRAT<sup>(5)</sup> |
| common stock | 2023-02-28 |  | S<sup>(1)</sup> |  | 786299 | D | <sup>(1)</sup> | 0 | I | by family trust<sup>(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) All of the shares reported as sold on this Form 4 were sold to the issuer for aggregate consideration of $1,888,814.77 in cash plus certain intellectual property rights and other assets, as part of the private transaction described in the issuer's Current Report on Form 8-K filed on February 28, 2023 with the Securities and Exchange Commission.

(2) These shares were held by the Josep Bassaganya-Riera Revocable Trust dated April 9, 2018, as amended (the "2018 Trust"). The Reporting Person is the sole trustee of the 2018 Trust and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaimed beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

(3) These shares were held by the Josep Bassaganya-Riera Grantor Retained Annuity Trust No. 1 dated June 28, 2018 (the "2018 GRAT"). The Reporting Person is the sole trustee of the 2018 GRAT and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaimed beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

(4) These shares were held by the Josep Bassaganya-Riera Grantor Retained Annuity Trust No. 2 dated March 26, 2019 (the "2019 GRAT"). The Reporting Person is the sole trustee of the 2019 GRAT and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaimed beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

(5) These shares were held by the Josep Bassaganya-Riera Grantor Retained Annuity Trust No. 3 dated August 3, 2022 (the "2022 GRAT"). The Reporting Person is the sole trustee of the 2022 GRAT and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaimed beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

(6) These shares were held by the Raquel Hontecillas-Magarzo Irrevocable Family Trust dated October 1, 2021 (the "2021 Family Trust"). The Reporting Person is the sole trustee of the 2021 Family Trust and the beneficiaries are the Reporting Person and the Reporting Person's immediate family members. The Reporting Person disclaimed beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

**Signature:** Josep Bassaganya-Riera  
**Date:** 2023-03-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**